Short Interest in Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Increases By 16.7%

Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 700 shares, an increase of 16.7% from the February 13th total of 600 shares. Based on an average daily volume of 17,100 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company’s stock are short sold.

Tema Cardiovascular and Metabolics ETF Trading Up 0.2 %

HRTS traded up $0.06 during trading on Wednesday, hitting $30.05. 4,155 shares of the company’s stock traded hands, compared to its average volume of 13,432. The company’s 50 day simple moving average is $30.01 and its two-hundred day simple moving average is $31.62. Tema Cardiovascular and Metabolics ETF has a 12-month low of $28.56 and a 12-month high of $36.03. The stock has a market capitalization of $69.12 million, a price-to-earnings ratio of 32.63 and a beta of 0.93.

Institutional Trading of Tema Cardiovascular and Metabolics ETF

An institutional investor recently raised its position in Tema Cardiovascular and Metabolics ETF stock. Sterling Investment Advisors Ltd. raised its holdings in shares of Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) by 5.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 167,703 shares of the company’s stock after purchasing an additional 9,008 shares during the period. Tema Cardiovascular and Metabolics ETF makes up about 1.2% of Sterling Investment Advisors Ltd.’s investment portfolio, making the stock its 24th largest holding. Sterling Investment Advisors Ltd. owned 7.29% of Tema Cardiovascular and Metabolics ETF worth $4,842,000 at the end of the most recent quarter.

Tema Cardiovascular and Metabolics ETF Company Profile

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive.